Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: A phase II Southwest Oncology Group Study (S0415)

INTRODUCTION: Esophageal adenocarcinomas commonly express the Epidermal Growth Factor Receptor (EGFR). This trial assessed the six month overall survival probability in metastatic esophageal cancer patients treated with cetuximab as second line therapy. METHODS: This was a multicenter, open-label ph...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gold, Philip J., Goldman, Bryan, Iqbal, Syma, Leichman, Lawrence P., Zhang, Wu, Lenz, Heinz-Josef, Blanke, Charles D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2010
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2928397/
https://ncbi.nlm.nih.gov/pubmed/20631636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181e77a92
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak